Emergent BioSolutions (EBS) Misses Q4 EPS by 81c
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $8.01 -0.5%
Revenue Growth %: +32.0%
Financial Fact:
Total other income (expense): -1.93M
Today's EPS Names:
CCEL, MHGU, PLG, More
Revenue Growth %: +32.0%
Financial Fact:
Total other income (expense): -1.93M
Today's EPS Names:
CCEL, MHGU, PLG, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q4 EPS of ($0.43), $0.81 worse than the analyst estimate of $0.38. Revenue for the quarter came in at $148.7 million versus the consensus estimate of $237 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sanuwave Q2 2026 revenue tops revised guidance range
- Jefferies Upgrades Salzgitter AG (SZG:GR) (SZGPY) to Buy
- Tavia and Vita Inclinata sign LOI for $450M SPAC merger
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
